Unlike traditional approaches, Immunethep's vaccine doesn't kill bacteria. Instead, it neutralizes a virulence mechanism bacteria use to shut down the immune system. This restores the body's natural ability to fight infection, a novel strategy analogous to checkpoint inhibitors in oncology.

Unlike existing MS therapies that primarily manage inflammatory relapses, Immunic's experimental drug has a dual mechanism. It both curbs inflammation and directly protects neurons from cell death, addressing the underlying disability progression that current treatments largely fail to stop.

The company’s informatics platform analyzes gene expression data to determine the optimal timing for its deep cyclic inhibition. This allows them to engineer the drug's pharmacodynamics—how long to shut down a pathway and when to release it—to maximize efficacy while minimizing resistance and toxicity.

Instead of directly competing with dominant anti-CD20 therapies, Immunic strategically targets patients who need to switch due to side effects like infection risk. This go-to-market strategy carves out a valuable niche as a safer, long-term oral alternative without needing to prove superior efficacy upfront.

The current boom in immunology and autoimmune (I&I) therapeutics is not a separate phenomenon but a direct consequence of capital and knowledge from immuno-oncology. Many of the same biological pathways are being targeted, simply modulated down (for autoimmune) instead of up (for cancer), allowing for rapid therapeutic advancement and platform reuse.

Despite significant progress in managing symptoms for autoimmune conditions, very few treatments fundamentally alter the disease's course. The major unmet needs and investment opportunities lie in therapies that can induce remission or target common underlying pathologies like fibrosis, moving beyond mere symptom relief.

The same cellular mechanism (NMT) hijacked by cancer cells is also exploited by viruses like HIV and coronaviruses for replication. By inhibiting NMT, Zelenorstat could potentially halt viral spread, making it a candidate for future pandemic defense.

While T-regs are most commonly associated with autoimmune conditions, Coya focuses on neurodegeneration. This strategy is based on their founder's research showing T-reg dysfunction is a major driver of diseases like ALS and FTD, applying a known biological mechanism to a novel, high-unmet-need therapeutic area.

The T-cell delivery system is versatile. It can carry T-cell engagers for cancer, but also antibodies for Alzheimer's or oligonucleotides. By using different T-cell types (like regulatory T-cells), it can also be used to reduce inflammation, expanding its applicability beyond oncology.